

OSENI - (12.5mg;15/30/45mg,25mg;15/30/45mg, Tablet)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE | Innovator | Takeda |
| Dosage | 12.5mg;15/30/45mg,25mg;15/30/45mg, Tablet | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both alogliptin and pioglitazone is appropriate | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.